p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling (DOI:10.1016/j.cell.2008.06.028);p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling

Cell

Volumn 134, Issue 3, 2008, Pages 451-460

  Budanov, Andrei V ^a   Karin, Michael ^a  

^a San Diego   (United States)

Author keywords

SIGNALING

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN DERIVATIVE; PROTEIN P53; SESTRIN1; SESTRIN2; TUBERIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; EMBRYO; GENE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION;

MUS;

EID: 48449101433     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2009.01.012     Document Type: Erratum

References (50)

1. Astrinidis A., Cash T.P., Hunter D.S., Walker C.L., Chernoff J., and Henske E.P. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene 21 (2002) 8470-8476
2. Averous J., and Proud C.G. When translation meets transformation: The mTOR story. Oncogene 25 (2006) 6423-6435
3. Averous J., Fonseca B.D., and Proud C.G. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene 27 (2007) 1106-1113
4. Budanov A.V., Shoshani T., Faerman A., Zelin E., Kamer I., Kalinski H., Gorodin S., Fishman A., Chajut A., Einat P., et al. Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability. Oncogene 21 (2002) 6017-6031
5. Budanov A.V., Sablina A.A., Feinstein E., Koonin E.V., and Chumakov P.M. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 304 (2004) 596-600
6. Buhler R., Lindros K.O., Nordling A., Johansson I., and Ingelman-Sundberg M. Zonation of cytochrome P450 isozyme expression and induction in rat liver. Eur. J. Biochem. 204 (1992) 407-412
7. Burnett P.E., Barrow R.K., Cohen N.A., Snyder S.H., and Sabatini D.M. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. USA 95 (1998) 1432-1437
8. Corradetti M.N., and Guan K.L. Upstream of the mammalian target of rapamycin: Do all roads pass through mTOR?. Oncogene 25 (2006) 6347-6360
9. Dames S.A., Mulet J.M., Rathgeb-Szabo K., Hall M.N., and Grzesiek S. The solution structure of the FATC domain of the protein kinase target of rapamycin suggests a role for redox-dependent structural and cellular stability. J. Biol. Chem. 280 (2005) 20558-20564
10. Dufner A., and Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp. Cell Res. 253 (1999) 100-109
11. Feng Z., Zhang H., Levine A.J., and Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl. Acad. Sci. USA 102 (2005) 8204-8209
12. Feng Z., Hu W., de Stanchina E., Teresky A.K., Jin S., Lowe S., and Levine A.J. The regulation of AMPK {beta}1, TSC2, and PTEN expression by p53: Stress, cell and tissue dpecificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 67 (2007) 3043-3053
13. Fingar D.C., and Blenis J. Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23 (2004) 3151-3171
14. Fingar D.C., Richardson C.J., Tee A.R., Cheatham L., Tsou C., and Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 24 (2004) 200-216
15. Florenes V.A., Maelandsmo G.M., Forus A., Andreassen A., Myklebost O., and Fodstad O. MDM2 gene amplification and transcript levels in human sarcomas: Relationship to TP53 gene status. J. Natl. Cancer Inst. 86 (1994) 1297-1302
16. Garami A., Zwartkruis F.J., Nobukuni T., Joaquin M., Roccio M., Stocker H., Kozma S.C., Hafen E., Bos J.L., and Thomas G. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11 (2003) 1457-1466
17. Guan L., Song K., Pysz M.A., Curry K.J., Hizli A.A., Danielpour D., Black A.R., and Black J.D. PKC-mediated down-regulation of cyclin D1 involves activation of the translational repressor 4E-BP1 via a PI3K/Akt-independent, PP2A-dependent mechanism in intestinal epithelial cells. J. Biol. Chem. 282 (2007) 14213-14225
18. Guertin D.A., and Sabatini D.M. An expanding role for mTOR in cancer. Trends Mol. Med. 11 (2005) 353-361
19. Guertin D.A., and Sabatini D.M. Defining the Role of mTOR in Cancer. Cancer Cell 12 (2007) 9-22
20. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 18 (2004) 1926-1945
21. Horton L.E., Bushell M., Barth-Baus D., Tilleray V.J., Clemens M.J., and Hensold J.O. p53 activation results in rapid dephosphorylation of the eIF4E-binding protein 4E-BP1, inhibition of ribosomal protein S6 kinase and inhibition of translation initiation. Oncogene 21 (2002) 5325-5334
22. Inoki K., Zhu T., and Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 (2003) 577-590
23. Inoki K., Li Y., Xu T., and Guan K.L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17 (2003) 1829-1834
24. Jonkers J., Meuwissen R., van der Gulden H., Peterse H., van der Valk M., and Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29 (2001) 418-425
25. Kwiatkowski D.J., and Manning B.D. Tuberous sclerosis: A GAP at the crossroads of multiple signaling pathways. Hum. Mol. Genet. 14 Spec No. 2 (2005) R251-R258
26. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
27. Levine A.J., Feng Z., Mak T.W., You H., and Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev. 20 (2006) 267-275
28. Mamane Y., Petroulakis E., Rong L., Yoshida K., Ler L.W., and Sonenberg N. eIF4E-from translation to transformation. Oncogene 23 (2004) 3172-3179
29. Motoshima H., Goldstein B.J., Igata M., and Araki E. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J. Physiol. 574 (2006) 63-71
30. Peeters H., Debeer P., Bairoch A., Wilquet V., Huysmans C., Parthoens E., Fryns J.P., Gewillig M., Nakamura Y., Niikawa N., et al. PA26 is a candidate gene for heterotaxia in humans: Identification of a novel PA26-related gene family in human and mouse. Hum. Genet. 112 (2003) 573-580
31. Pende M., Um S.H., Mieulet V., Sticker M., Goss V.L., Mestan J., Mueller M., Fumagalli S., Kozma S.C., and Thomas G. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol. Cell. Biol. 24 (2004) 3112-3124
32. Postic C., Shiota M., Niswender K.D., Jetton T.L., Chen Y., Moates J.M., Shelton K.D., Lindner J., Cherrington A.D., and Magnuson M.A. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J. Biol. Chem. 274 (1999) 305-315
33. Ragnarsson G., Eiriksdottir G., Johannsdottir J.T., Jonasson J.G., Egilsson V., and Ingvarsson S. Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br. J. Cancer 79 (1999) 1468-1474
34. Richter J.D., and Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433 (2005) 477-480
35. Sabatini D.M. mTOR and cancer: Insights into a complex relationship. Nat. Rev. Cancer 6 (2006) 729-734
36. Sablina A.A., Budanov A.V., Ilyinskaya G.V., Agapova L.S., Kravchenko J.E., and Chumakov P.M. The antioxidant function of the p53 tumor suppressor. Nat. Med. 11 (2005) 1306-1313
37. Sarbassov D.D., and Sabatini D.M. Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J. Biol. Chem. 280 (2005) 39505-39509
38. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., Tempst P., and Sabatini D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14 (2004) 1296-1302
39. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., and Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22 (2006) 159-168
40. Schwab M., Praml C., and Amler L.C. Genomic instability in 1p and human malignancies. Genes Chromosomes Cancer 16 (1996) 211-229
41. Soliman G.A. The mammalian target of rapamycin signaling network and gene regulation. Curr. Opin. Lipidol. 16 (2005) 317-323
42. Tee A.R., Manning B.D., Roux P.P., Cantley L.C., and Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13 (2003) 1259-1268
43. Thomas G.V. mTOR and cancer: Reason for dancing at the crossroads?. Curr. Opin. Genet. Dev. 16 (2006) 78-84
44. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
45. Velasco-Miguel S., Buckbinder L., Jean P., Gelbert L., Talbott R., Laidlaw J., Seizinger B., and Kley N. PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes. Oncogene 18 (1999) 127-137
46. Verna L., Whysner J., and Williams G.M. N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol. Ther. 71 (1996) 57-81
47. Vousden K.H., and Lane D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8 (2007) 275-283
48. Wullschleger S., Loewith R., and Hall M.N. TOR signaling in growth and metabolism. Cell 124 (2006) 471-484
49. Yang Q., and Guan K.L. Expanding mTOR signaling. Cell Res. 17 (2007) 666-681
50. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108 (2001) 1167-1174